Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 242

1.

Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction.

Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH.

J Clin Psychiatry. 2005 Jan;66(1):41-8.

2.

Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection.

Mahajan S, Avasthi A, Grover S, Chawla YK.

J Psychosom Res. 2014 Aug;77(2):109-15. doi: 10.1016/j.jpsychores.2014.05.008. Epub 2014 Jun 2.

PMID:
25077851
3.

Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.

Pavlović Z, Delić D, Marić NP, Vuković O, Jašović-Gašić M.

Psychiatr Danub. 2011 Dec;23(4):370-7.

4.

Depressive symptoms and viral clearance in patients receiving interferon-alpha and ribavirin for hepatitis C.

Raison CL, Broadwell SD, Borisov AS, Manatunga AK, Capuron L, Woolwine BJ, Jacobson IM, Nemeroff CB, Miller AH.

Brain Behav Immun. 2005 Jan;19(1):23-7.

PMID:
15581735
5.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
6.

Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C.

Comai S, Cavalletto L, Chemello L, Bernardinello E, Ragazzi E, Costa CV, Bertazzo A.

Pharmacol Res. 2011 Jan;63(1):85-92. doi: 10.1016/j.phrs.2010.10.009. Epub 2010 Oct 19.

PMID:
20940053
7.

Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study.

Reichenberg A, Gorman JM, Dieterich DT.

AIDS. 2005 Oct;19 Suppl 3:S174-8.

PMID:
16251815
8.

Changes in depressive symptoms and impact on treatment course among hepatitis C patients undergoing interferon-α and ribavirin therapy: a prospective evaluation.

Chapman J, Oser M, Hockemeyer J, Weitlauf J, Jones S, Cheung R.

Am J Gastroenterol. 2011 Dec;106(12):2123-32. doi: 10.1038/ajg.2011.252. Epub 2011 Aug 9.

PMID:
21826113
9.

Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.

Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T.

AIDS. 2004 Jan 2;18(1):75-9.

PMID:
15090832
10.

Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.

Bani-Sadr F, Lapidus N, Melchior JC, Ravaux I, Bensalem M, Rosa I, Cacoub P, Pol S, Perronne C, Carrat F.

J Viral Hepat. 2008 Apr;15(4):255-60. doi: 10.1111/j.1365-2893.2007.00939.x.

PMID:
18307589
11.

Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

Sockalingam S, Balderson K.

Int Clin Psychopharmacol. 2005 Sep;20(5):289-90.

PMID:
16096520
12.

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

Jacobson IM, Gonzalez SA, Ahmed F, Lebovics E, Min AD, Bodenheimer HC Jr, Esposito SP, Brown RS Jr, Bräu N, Klion FM, Tobias H, Bini EJ, Brodsky N, Cerulli MA, Aytaman A, Gardner PW, Geders JM, Spivack JE, Rahmin MG, Berman DH, Ehrlich J, Russo MW, Chait M, Rovner D, Edlin BR.

Am J Gastroenterol. 2005 Nov;100(11):2453-62.

PMID:
16279900
13.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
14.

CTN-194 (PICCO): design of a trial of citalopram for the prevention of depression and its consequences in HIV-hepatitis C co-infected individuals initiating pegylated interferon/ribavirin therapy.

Klein MB, Cooper C, Brouillette MJ, Sheehan NL, Benkelfat C, Annable L, Weston F, Kraus D, Singer J; CTN194 Investigators.

Contemp Clin Trials. 2008 Jul;29(4):617-30. doi: 10.1016/j.cct.2008.01.001. Epub 2008 Jan 12.

PMID:
18262853
15.

DEPRESSIVE EPISODE INCIDENCE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON AND RIBAVIRIN.

Vabo IL, Ferreira LE, Pace FH.

Arq Gastroenterol. 2016 Jan-Mar;53(1):20-4. doi: 10.1590/S0004-28032016000100005.

16.

Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.

Sood A, Midha V, Hissar S, Kumar M, Suneetha PV, Bansal M, Sood N, Sakhuja P, Sarin SK.

J Gastroenterol Hepatol. 2008 Feb;23(2):203-7. Epub 2007 Jul 20.

PMID:
17645472
17.

Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.

Fumaz CR, Muñoz-Moreno JA, Ballesteros AL, Paredes R, Ferrer MJ, Salas A, Fuster D, Masmitjà E, Pérez-Alvarez N, Gómez G, Tural C, Clotet B.

AIDS Care. 2007 Jan;19(1):138-45.

PMID:
17129869
18.

Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.

Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.

Transpl Int. 2007 Jul;20(7):583-90. Epub 2007 Apr 13.

19.

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.

Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky E, Strauss R, Bernstein D, Flamm S, Pauly MP, Mukhopadhyay P, Griffel LH, Brass CA; WIN-R Study Group.

Hepatology. 2007 Oct;46(4):971-81.

PMID:
17894303
20.

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin.

Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdés A, Martell M, Esteban R.

Hepatology. 2002 Apr;35(4):930-6.

PMID:
11915041

Supplemental Content

Support Center